Whether the improved durability of response with OLUTA compared to IVO in R/R-AML is due to its allosteric inhibition of mutant IDH1 or through suppression of resistance mechanisms observed with IVO remains unknown. The gene discussed is IDH1; the disease is acute myeloid leukemia.